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Insomnia is a common disorder linked with adverse long-term medical and psychiatric 
outcomes. The underlying pathophysiological processes and causal relationships of insomnia 
with disease are poorly understood. Here we identify 57 loci for self-reported insomnia 
symptoms in the UK Biobank (n = 453,379) and confirm their impact on self-reported 
insomnia symptoms in the HUNT study (n = 14,923 cases, 47,610 controls), physician-
diagnosed insomnia in Partners Biobank (n = 2,217 cases, 14,240 controls), and 
accelerometer-derived measures of sleep efficiency and sleep duration in the UK Biobank (n 
= 83,726). Our results suggest enrichment of genes involved in ubiquitin-mediated 
proteolysis and of genes expressed in multiple brain regions, skeletal muscle, and adrenal 
gland. Evidence of shared genetic factors is found between frequent insomnia symptoms and 
restless legs syndrome, aging, cardio-metabolic, behavioral, psychiatric and reproductive 
traits.  Evidence is found for a possible causal link between insomnia symptoms and coronary 
artery disease, depressive symptoms and subjective well-being. 
 
 Insomnia disorder, persistent difficulty in initiating or maintaining sleep, and 
corresponding daytime dysfunction, occurs in 10-20% of the population1. Up to one-third of the 
population experience transient insomnia symptoms at any given time2. Longitudinal studies 
suggest that insomnia increases the risk for developing anxiety disorders, alcohol abuse, major 
depression, and cardio-metabolic disease3. However, little is known about underlying 
pathophysiologic mechanisms. Cognitive-behavioral therapies are the recommended first-line 
treatment, but many barriers to treatment exist4,5. Common drug treatments target synaptic 
neurotransmission (via GABAergic pathways), hypothalamic neuropeptides (via 
hypocretin/orexin), cortical arousal (via histamine receptors), or the melatonin system, but these 
drugs have variable effectiveness, may be habit forming, and have side effects6,7. Therefore, it is 
necessary to develop new personalized therapeutic strategies. Model organism studies have 
identified genes involved in sleep processes8–13. Family-based heritability estimates suggest that 
insomnia has a genetic component (22%–25%)14. Recent GWAS reported four loci for insomnia 
symptoms15,16, but insights into underlying biological pathways and causal genetic links with 
disease are limited.  
UK Biobank participants of European ancestry (n = 453,379) self-reported insomnia 
symptoms to the question “do you have trouble falling asleep at night or do you wake up in the 
middle of the night?”. In this sample, 29% of individuals self-reported frequent insomnia 
symptoms (“usually”), with a higher prevalence in women (32% vs. 24%) and in older participants, 
shift workers, and those with shorter self-reported sleep duration (Supplementary Table 1).  
  
We performed two parallel GWAS: (i) frequent insomnia symptoms (“never/rarely” vs. 
“usually” insomnia symptoms, n = 129,270 cases and 108,357 controls); (ii) any insomnia 
symptoms (“never/rarely” vs. “sometimes”/“usually” insomnia symptoms, n = 345,022 cases and 
108,357 controls), adjusting for age and sex using 14,661,600 genotyped and imputed genetic 
variants across the autosomes and genotyped variants on the X chromosome. We identified 57 
association signals explaining 1% of the variance (Fig. 1, Supplementary Table 2, and 
Supplementary Figs. 1 and 2). Of these, 20 loci were identified in both analyses, 28 loci in analysis 
of frequent insomnia symptoms only, and 9 in analysis of any insomnia symptoms only 
(Supplementary Table 2). Conditional analyses identified no secondary association signals. The 
57 associations were independent of insomnia risk factors, as sensitivity analyses adjusting for 
body mass index (BMI), lifestyle, caffeine consumption, and depression or recent stress did not 
notably alter the magnitude or direction of effect estimates (Supplementary Table 3). The MEIS1 
association signal identified in the interim release of the UK Biobank was confirmed in the 
remainder of the UK Biobank sample (n = 75,508 cases of frequent insomnia symptoms and 64,403 
controls; rs113851554 T, OR (95% CI) = 1.19 (1.15-1.23), P = 1.5 x 10-21), and nominal replication 
was seen for previously reported CYCL1 (P = 9.0 x 10-3). The TMEM132E and SCFD2 signals 
showed concordant direction of effect in both UK Biobank sub-samples, but were not significant, 
perhaps reflecting selection bias in the interim release sample17. No other findings from previous 
candidate gene association studies or smaller GWAS were confirmed (Supplementary Table 4).  
Secondary GWAS excluding current shift workers or individuals reporting hypnotic, anti-
anxiolytic or psychiatric medication usage, and/or with selected chronic diseases or psychiatric 
illnesses (excluding n = 76,470 participants) revealed strong pair-wise genetic correlation to the 
primary GWAS (rg ~ 1) and did not identify additional association signals (Supplementary Figs. 
1-3). Thus, biological processes underlying pathophysiology of insomnia symptoms may be 
common between the general population and those with co-morbidities, in accordance with the 
recent clinical reclassification of primary and secondary insomnia diagnoses into an insomnia 
disorder18.  
The prevalence of insomnia symptoms varies by sex; therefore, we performed secondary 
sex stratified GWAS (Supplementary Table 5). As described previously15,16, the genetic 
architecture for frequent insomnia symptoms differed by sex, with a genetic correlation between 
the stratified GWAS of rg = 0.807 (Supplementary Fig. 3). We found 13 additional loci (8 in women 
and 5 in men), although there were no genome-wide significant sex interactions. Effects in women 
were not modified by menopausal status.  
Self-report of insomnia symptoms has limitations, including recall bias and lack of 
granularity19. Therefore, we sought replication of association signals in the HUNT population 
study with self-reported insomnia symptoms (n = 14,923 cases, 47,610 controls; Supplementary 
Table 6)20 and the Partners Biobank with physician-diagnosed insomnia (n = 2,217 cases, 14,240 
controls).  Replication was observed for the MEIS1 variant in both cohorts, and a genetic risk score 
(GRS) using our 57 variants and weighted by the effect estimates from GWAS of frequent 
insomnia symptoms (provided in Supplementary Table 2) was also associated with insomnia 
symptoms in HUNT (OR (95%CI) = 1.015 (1.01-1.02) per allele, P = 2.71 x 10-11) and the Partners 
Biobank (OR (95%CI) 1.017 (1.007-1.027) per allele, P = 8.88 x 10-4) (Table 1 and Supplementary 
Table 8). A meta-analysis of the UK Biobank, HUNT, and Partners Biobank studies shows 
consistency across all three cohorts (Supplementary Table 2). Next, to investigate impact of 
genetic variants on objective sleep patterns, we tested the 57 lead variants for association with 8 
  
activity-monitor sleep measures in a subset of the UK Biobank participants of European ancestry 
who had undergone up to 7 days of wrist-worn accelerometry (n = 84,745; Supplementary Table 
6). The lead MEIS1 risk variant was associated with a higher number of sleep episodes, indicating 
an interrupted sleep pattern, lower sleep efficiency, shorter sleep duration and later sleep timing 
(P < 0.0008; Supplementary Table 9). The GRS was associated with reduced sleep efficiency 
(difference = -0.04 (0.01) % per allele; P = 4 x 10-14), shorter sleep duration (difference = -0.25 
(0.035) minutes per allele; P = 8 x 10-13), and greater day-to-day variability in sleep duration 
(difference = 0.077 (0.025) minutes per allele; P = 0.0017) but not with the number of sleep 
episodes or diurnal inactivity duration (Table 1 and Supplementary Table 9). 
In order to gain insight into the probable causal variants underlying the 57 association 
signals, we performed fine-mapping in PICS21 and identified 38 variants with a causal probability 
of 0.20 or greater (Supplementary Table 10 and Supplementary Fig. 4)22. This list includes 
missense variants in NAD kinase NADK (N262K) and MDGA1 (L61P), as well as rs324017, a 
SNP within the gene encoding transcriptional repressor NAB1 (EGR-1 binding protein) that is 
predicted to disrupt a binding site for EGR1 (Supplementary Table 10), a transcription factor 
involved in response to stress23 and synaptic plasticity during REM sleep23. 
The 57 insomnia symptoms loci lie in genomic regions encompassing up to 236 genes, and 
a summary of annotations for signals or genes within each locus is shown in Supplementary Table 
11. Association signals at 14 loci overlapped with NHGRI GWAS signals (r2 > 0.7 in 1KG CEU) 
for one or more complex traits, with the insomnia symptoms risk allele associated with a greater 
risk of restless legs syndrome, schizophrenia, Tourette’s syndrome, or obsessive-compulsive 
disorder, and associated with higher systolic blood pressure, greater carotid plaque burden, lower 
age at menarche and influencing adiposity traits, height, and educational attainment. Notably, 
experimental studies in mouse or fly models have implicated five genes at three associated loci in 
sleep regulation (DVL1, LRP1, NR1H3, PRKAR2A, and SEMA3F). Genes within 16 loci are known 
drug targets.  
Two lead SNPs were associated with one or more of 3,144 human brain structure and 
function traits assessed in the UK Biobank (P < 2.8 x 10-7, n = 9,707; Oxford Brain Imaging 
Genetics Server)24, including rs1544637 (within a transcript LOC642659) with several large white 
matter tracts and with cingulate gyrus morphometry, which has previously been connected to 
insomnia25, and rs62158170 (near PAX8) with resting-state fMRI networks (Supplementary Fig. 
5).  
Gene-based tests26 identified 135 associated genes (P ≤ 2.29 x 10-6; Supplementary Table 
12). These genes are enriched for expression in brain regions9 (Supplementary Table 13), including 
the cerebellum (P = 1.3 x 10-6), frontal cortex (P = 1.3 x 10-5), anterior cingulate cortex (P = 1.7 x 
10-5), hypothalamus (P = 2.2 x 10-5), basal ganglia (P = 7.0 x 10-4), amygdala (P = 3.4 x 10-4), and 
hippocampus (P = 8.4 x 10-4), in line with previous research linking these brain regions to 
insomnia25,27 and mouse single-cell studies linking insomnia GWAS hits to specific populations 
of brain cells28. Integration of gene expression data with GWAS using transcriptome-wide 
association analyses29 identified 24 genes where insomnia-SNPs influence gene expression in one 
or more of 14 tissue types tested, including eight brain regions, muscles, peripheral nerves, whole 
blood, pituitary, thyroid, and adrenal gland tissue (Supplementary Table 16).  
SNP-based heritability of frequent insomnia symptoms was estimated at h2 = 16.7%30. 
Partitioning of heritability across tissue types31,32 confirmed enrichment in the central nervous 
  
system, adrenal/pancreas tissue, and skeletal muscle (P < 10-5) (Supplementary Table 17). 
Partitioning across functional class implicated activation and repression of enhancers 
(Supplementary Table 17). Pathway and ontology analyses26,33,34 reveal a significant role for 
ubiquitin mediated proteolysis (Pbonf = 0.04; Supplementary Table 14), similar to findings in recent 
GWAS of RLS35, and suggestive roles for phototransduction and muscle tissue development, 
across several databases (Supplementary Tables 14 and 15). Evidence from model organisms 
supports the link between Cullin-3 mediated ubiquitination and sleep/circadian rhythms36–39. 
Furthermore, the restless legs syndrome (RLS) gene BTBD9 has been implicated as a substrate 
adaptor for E3 ubiquitin ligases40. We find no evidence for enrichment of neurotransmission 
receptor or biosynthesis genes known to be involved in the regulation of sleep (e.g. GABA, 
glutamate, adenosine).   
We investigated the genetic link between frequent insomnia symptoms and other 
behavioral and/or disease states. Based on previous links between RLS and insomnia 
symptoms15,16, we tested a GRS of 20 SNPs for RLS35 and found association with frequent 
insomnia symptoms (OR = 1.03 (1.02-1.04) per RLS risk allele, P = 2.57 x 10-57), driven partly by 
the MEIS1 region (GRS excluding MEIS1 region OR = 1.02 (1.02-1.03) per RLS risk allele, P = 
2.06 x 10-31)(Supplementary Table 18 and Supplementary Fig. 6). We also tested a GRS of our 57 
insomnia SNPs in RLS and found an association with RLS (OR = 1.39 (1.34-1.44), P = 1.70 x 10-
80) driven partly by the MEIS1 signal (GRS excluding MEIS1 region OR = 1.17 (1.13-1.21), P = 
2.56 x 10-20) (Supplementary Table 18).  We also observe a positive genetic correlation between 
insomnia and RLS (rg = 0.291, P = 6.33 x 10
-12).  We performed BUHMBOX analysis to 
distinguish between pleiotropy and heterogeneity. BUHMBOX41 analyses using all 20 RLS SNPs 
points towards heterogeneity (P = 4.09 x 10-6), most likely due to undiagnosed RLS cases 
misclassified as insomnia. However, when we exclude the MEIS1 locus, we detect a possible 
shared genetic basis not explained by heterogeneity (P = 0.137).   
To test the proportion of variance frequent insomnia symptoms shares with other traits 
based on genetic overlap, we performed genetic correlation analyses with 233 traits with public 
GWAS summary statistics31,32,42,43. We found strong positive genetic correlations (P ≤ 2 x 10-3) 
between frequent insomnia symptoms and adiposity traits, coronary artery disease, number of 
children ever born, neuroticism, smoking behavior, and depressive symptoms and disorder. Strong 
negative genetic correlations were observed with self-reported sleep duration, subjective well-
being, cognitive measures, proxy longevity measures, and the remaining reproductive traits (Fig. 
2 and Supplementary Table 19). These genetic links persisted with GWAS excluding subjects with 
chronic and psychiatric illnesses (Supplementary Table 19), indicating a relationship not driven 
by the presence of concomitant conditions.  
To test for causal links between frequent insomnia symptoms and seven clusters of 
genetically correlated traits, we performed Mendelian randomization (MR) analyses mostly within 
a two-sample summary data framework. Using the inverse variance (IVW) method44 (Fig. 3 and 
Supplementary Table 20), we found evidence of a causal association (P < 0.001) between frequent 
insomnia symptoms and prevalent coronary artery disease (CAD; OR (95%CI) = 2.15 (1.38-3.35)) 
reduced subjective well-being  (difference in mean SD units of -0.29 (s.e. 0.06)), greater depressive 
symptoms (difference in mean SD units of 0.42 (s.e. 0.08)); all associations had a consistent 
direction and similar magnitude of effect in sensitivity analyses using MR-Egger45 and weighted 
median methods (Fig. 3 and Supplementary Table 20)46. We found similar results using effect 
estimates from GWAS excluding those with preexisting conditions. We validated the causal 
  
association between insomnia and CAD with one-sample MR in the UK Biobank (n = 23,980 cases 
and 361,706 controls, OR (95%CI) = 2.95 (2.18–3.99), P = 2.3 x 10-12) (Supplementary Table 20 
and Supplementary Fig. 7). Bidirectional MR identified no evidence of reverse causality. The one-
sample MR causal association between insomnia status and CAD in UK Biobank is consistent 
with the robust empirical evidence seen in prospective studies and meta-analyses3,47. 
This study provides a comprehensive description of the genetic architecture of frequent or 
persistent insomnia symptoms, pointing to putative causal variants and candidate genes, pathways 
and tissues for functional studies. Further, we define physiological correlates for insomnia 
symptoms and meaningful clinical links, including a causal link with CAD.  
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Table 1 | A risk score of genetic variants for self-reported insomnia symptoms (57 SNPs) associates with self-reported insomnia symptoms in the HUNT study, physician diagnosed  
insomnia in the Partners Biobank, and activity-monitor based measures of sleep fragmentation, timing and duration from 7 day accelerometry in the UK Biobank 
    
Frequent insomnia symptoms 
Weighted GRS   
Frequent insomnia symptoms 
Weighted GRS excluding MEIS1 
  Trait OR 95% CI P   OR [95% CI] 
HUNT Study (n = 14,923 cases, 
47,610 controls) 
Self-reported insomnia 
symptoms 1.015 1.01-1.02 2.71x10-11   1.0130 
Partners Biobank (n = 2,217 cases, 
14,240 controls) Physician diagnosed insomnia  1.017 1.01-1.03 8.88x10-4   1.0120 
              
    Beta SE P   Beta (SE) 
UK Biobank 7-day accelerometry 
(n = 84,745) 
Sleep fragmentation measures           
   Sleep efficiency % -0.0400 0.010 4.21x10-14   -0.0300 
     Number of sleep bouts (n) 0.0053 0.002 0.030   0.0044 
  Sleep duration measures           
     Sleep duration (minutes) -0.2460 0.036 8.39x10-13   -0.2210 
  
   Sleep duration standard 
deviation (minutes) 0.0780 0.024 1.72x10-3   0.0750 
  Sleep timing measures           
  
   Midpoint of 5h daily period of 
minimum activity (L5 timing) 
(minutes) 0.0960 0.042 0.025   0.0580 
  
   Midpoint of 10 daily period of 
maximum activity (M10 timing) 
(minutes) 0.0420 0.048 0.429   0.0300 
  
   Diurnal inactivity duration 
(minutes) 0.0060 0.030 0.901   0.0080 
     Sleep midpoint (minutes) -0.0124 0.024 0.975   -0.0070 
Tested using a risk score weighted by effect of SNP on self-reported frequent insomnia symptoms in UK Biobank sample (Supplementary Table 2) in the gtx package in R or PLINK. 
SE, standard error; OR, odds ratio per risk allele; Beta, effect per risk allele; CI, 95% confidence interval. 
 
  
  
 
 
Figure 1 | Manhattan plots for genome-wide association analyses of insomnia. a, Frequent 
insomnia symptoms (ncases = 129,270, ncontrols = 108,352). b, Any insomnia symptoms (ncases = 
345,022, ncontrols = 108,352). Dotted line is genome-wide significant (P = 5 x 10
-8) results of 
linear mixed models adjusted for age, sex, principal components of ancestry, and genotyping 
array. SNP-based heritability estimates were calculated using BOLT-REML variance 
components analysis. Chromosomes are annotated with the nearest gene to each association 
signal. 
 
Figure 2 |  Shared genetic architecture between frequent insomnia symptoms and 
behavioral and disease traits. LD-score regression estimates of genetic correlation (rG) of 
frequent insomnia symptoms are compared with the summary statistics from 224 publicly 
available genome-wide association studies of psychiatric and metabolic disorders, immune 
diseases, and other traits of natural variation. Blue, positive genetic correlation; red, negative 
genetic correlation, rG values displayed for significant correlations. Larger squares correspond to 
more significant P-values. Genetic correlations that are significantly different from zero after 
Bonferroni correction are shown on the plot (after Bonferroni correction, P-value cut-off is 
0.0002). All genetic correlations in this report can be found in tabular form in Supplementary 
Table 19. IQ, intelligence quotient. 
 
Figure 3 | Causal relationships of insomnia symptoms. a-f, Association between single 
nucleotide polymorphisms associated with frequent insomnia symptoms and CAD (a), subjective 
well-being (c), and depressive symptoms (e). Per allele associations with risk plotted against per 
allele associations with frequent insomnia symptom risk (vertical and horizontal black lines 
around points show 95% confidence interval for each polymorphism) results are shown for three 
different MR association tests. Forest plots show the estimate of the effect of genetically 
increased insomnia risk on CAD (b), depressive symptoms (d), and subjective well-being (f) as 
assessed for each SNP. Nearest gene(s) is displayed to the right of plot. Also shown for each 
SNP is the 95% confidence interval (gray line segment) of the estimate and the Inverse Variance 
MR, MR-Egger, and Weighted Median MR results in red. Sample size of each GWAS used in 
the MR analyses is as follows: frequent insomnia symptoms (ncases = 129,270, ncontrols = 108,352), 
CAD (ncases = 60,801, ncontrols = 123,504), subjective well-being (n = 298,420), and depressive 
symptoms (n = 161,460). 
  
  
Methods 
UK Biobank population and study design. Study participants were from the UK Biobank study, 
described in detail elsewhere48. In brief, the UK Biobank is a prospective study of >500,000 people 
living in the United Kingdom. All people in the National Health Service registry aged 40-69 and 
living <25 miles from a study center were invited to participate between 2006-2010. In total, 
503,325 participants (5%) were recruited from over 9.2 million mailed invitations. Self-reported 
baseline data were collected by questionnaire and anthropometric assessments were performed. 
For the current analysis, individuals of non-white ethnicity (n = 48,667) were excluded to avoid 
confounding effects. A subset analysis was also performed excluding UK Biobank subjects from 
the interim release and their relatives (exclusion n = 190,216).   
 
Insomnia and covariate measures. Study subjects self-reported insomnia symptoms, depression, 
medication use, age, and sex on a touch-screen questionnaire at baseline assessment. Height and 
weight were measured at baseline. To assess insomnia symptoms, subjects were asked, “Do you 
have trouble falling asleep at night or do you wake up in the middle of the night?" with responses 
“never/rarely”, “sometimes”, “usually”, “prefer not to answer”. Subjects who responded “Prefer 
not to answer” (n = 637) were set to missing. We undertook two GWAS, one in which insomnia 
symptoms were dichotomized into controls (“never/rarely”) and cases with any symptoms 
(“sometimes” and “usually”), and the second in which participants were dichotomized into 
controls (“never/rarely”) or frequent insomnia symptoms (“usually”), with those reporting 
“sometimes” excluded. Additional covariates used in sensitivity analyses included BMI, self-
reported and prevalent sleep apnea diagnosis, area deprivation index, alcohol intake, snoring, nap 
behavior, smoking status, menopause status, weekly physical activity, tea and coffee intake, 
depression, and extreme stress. BMI was calculated from measured height and weight at baseline 
visit. Prevalent sleep apnea cases were defined based on primary or secondary ICD10 diagnosis 
code (G47.3; n = 391 cases) at the time of baseline assessment. Social deprivation for participant 
area of residence at the time of recruitment was represented by the Townsend deprivation index, 
based on national census data immediately preceding participation in the UK Biobank. The 
Townsend deprivation index was log transformed for use in the analyses. Alcohol intake was self-
reported in response to the question “About how often do you drink alcohol?” with answers 
ranging from “daily or almost daily” to “never”. Snoring was reported in answer to the question 
“Does your partner or a close relative or friend complain about your snoring?”. Nap behavior was 
self-reported in response to the question “Do you have a nap during the day” with answers 
“never/rarely”, “sometimes”, or “usually”. Smoking status was self-reported as past smoking 
behavior and current smoking behavior, and classified into “current”, “past”, or “never” smoked. 
Menopause status was reported in answer to the question “Have you had your menopause (periods 
stopped)?” with answers “yes”, “no”, “not sure – had a hysterectomy”, “not sure – other reason”. 
Weekly physical activity in total metabolic equivalents per week, total MET-h/week, was 
calculated using self-reported estimates of type and duration of physical activity. Tea and coffee 
intake was estimated using the questions “How many cups of tea do you drink each day? (Include 
black and green tea)” and “How many cups of coffee do you drink each day? (Include 
decaffeinated coffee),” respectively, with responses in cups/day. Employment status was self-
reported in response to the following question “Which of the following describes your current 
situation?” with responses “in paid employment or self-employed”, “retired”, “looking after home 
  
and/or family”, “unable to work because of sickness or disability”, “unemployed”, doing unpair or 
voluntary work”, “full or part-time student”, “none of the above”, “prefer not to answer”. Marital 
status was derived from self-reported household occupancy and relatedness data as follows: 
married/partner was derived from those reporting husband/wife/partner in household with >1 
person reported to live in household.  Depression was reported in answer to the question “How 
often did you feel down, depressed or hopeless mood in last 2 weeks?” (cases, n = 4,242 based on 
answers “more than half the days”, or “nearly every day”). Extreme stress was assessed with the 
question “In the last two years have you experiences any of the following (you can select more 
than one answer” with responses “serious illness, injury or assault to yourself”, “serious illness, 
injury or assault of a close relative”, “death of a close relative”, “death of a spouse or partner”, 
“marital separation/divorce”, “financial difficulties”, “none of the above”. A secondary GWAS 
further excluded shift workers, sleep and psychiatric medication users, and subjects with chronic 
and psychiatric illness (n = 76,470). Cases of psychiatric disorder was determined using any of the 
following definitions (derived from Howard et al.): (i) ICD-10 codes for major depressive disorder 
(F32, F33), bipolar disorder (F30, F31), schizophrenia (F20-F29), autism (F84.0, F84.3, F84.5), 
intellectual disability (F70.0, F70.1, F70.9), anxiety disorder (F40 - F43), multiple personality 
disorder (F44.8), or mood disorder (F30 - F39); (ii) Self-reported antidepressant, antipsychotic, or 
anxiolytic use at nurse-led interview; (iii) Self-reported depression, major depressive disorder, 
bipolar disorder, or schizophrenia at nurse-led interview at baseline visit; (iv) “Broad depression”: 
responded yes to the question “Have you ever seen a general practitioner (GP) for nerves, anxiety, 
tension or depression?” and yes to either, “have you ever had a time when you were feeling 
depressed or down for at least a whole week,” or, “Have you ever had a time when you were 
uninterested in things or unable to enjoy the things you used to for at least a whole week?” lasting 
for more than 1 week; (v) Questionnaire-assessed bipolar disorder (Smith algorithm) responded 
yes to the question, “Have you ever had a period of time lasting at least two days when you were 
feeling so good, "high", excited or "hyper" that other people thought you were not your normal 
self or you were so "hyper" that you got into trouble?” or “Have you ever had a period of time 
lasting at least two days when you were so irritable that you found yourself shouting at people or 
starting fights or arguments?” for a duration of at least one week and with at least 3 manic/hyper 
symptoms49. A list of sleep medications can be found in the Supplementary Note.   
A description of coronary artery disease and activity monitor derived measures of sleep in 
the UK Biobank can be found in the Supplementary Note. 
 
Genotyping and quality control. Phenotype data is available for 502,631 subjects in the UK 
Biobank. Genotyping was performed by the UK Biobank, and genotyping, quality control, and 
imputation procedures are described in detail here50. In brief, blood, saliva, and urine was collected 
from participants, and DNA was extracted from the buffy coat samples. Participant DNA was 
genotyped on two arrays, UK BiLEVE and UKB Axiom with >95% common content and 
genotypes for ~800,000 autosomal SNPs were imputed to two reference panels. Genotypes were 
called using Affymetrix Power Tools software. Sample and SNPs for quality control were selected 
from a set of 489,212 samples across 812,428 unique markers. Sample QC was conducted using 
605,876 high quality autosomal markers. Samples were removed for high missingness or 
heterozygosity (968 samples) and sex chromosome abnormalities (652 samples). Genotypes for 
488,377 samples passed sample QC (~99.9% of total samples). Marker based QC measures were 
  
tested in the European ancestry subset (n = 463,844), which was identified based on principal 
components of ancestry. SNPs were tested for batch effects (197 SNPs/batch), plate effects (284 
SNPs/batch), Hardy-Weinberg equilibrium (572 SNPs/batch), sex effects (45 SNPs/batch), array 
effects (5417 SNPs), and discordance across control replicates (622 on UK BiLEVE Axiom array 
and 632 UK Biobank Axiom array) (P < 10-12 or <95% for all tests). For each batch (106 batches 
total), markers that failed at least one test were set to missing. Before imputation, 805,426 SNPs 
pass QC in at least one batch (>99% of the array content). Population structure was captured by 
principal component analysis on the samples using a subset of high quality (missingness <1.5%), 
high frequency SNPs (>2.5%) (~100,000 SNPs) and identified the sub-sample of white British 
descent. We further clustered subjects into four ancestry clusters using K-means clustering on the 
principal components, identifying 453,964 subjects of European ancestry. Imputation of autosomal 
SNPs was performed to UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference 
Consortium (HRC) with the current analysis using only those SNPs imputed to the HRC reference 
panel. Autosomal SNPs were pre-phased using SHAPEIT351 and imputed using IMPUTE4. In 
total ~96 million SNPs were imputed. Related individuals were identified by estimating kinship 
coefficients for all pairs of samples, using only markers weakly informative of ancestral 
background. In total, there are 107,162 related pairs comprised of 147,731 individuals related to 
at least one other subject in the UK Biobank. 
 
Genome-wide association analysis. Genetic association analysis across the autosomes was 
performed in related subjects of European ancestry (n = 453,964) using BOLT-LMM30 linear 
mixed models and an additive genetic model adjusted for age, sex, 10 PCs, genotyping array and 
genetic correlation matrix with a maximum per SNP missingness of 10% and per sample 
missingness of 40%. We used a genome-wide significance threshold of 5 x 10-8 for each GWAS. 
Genetic association analysis was also performed in unrelated subjects of white British ancestry (n 
= 337,545) using PLINK52 logistic regression and an additive genetic model adjusted for age, sex, 
10 PCs and genotyping array to determine SNP effects on self-reported insomnia symptoms. We 
used a hard-call genotype threshold of 0.1, SNP imputation quality threshold of 0.80, and a MAF 
threshold of 0.001. Genetic association analysis for the X chromosome was performed using the 
genotyped markers on the X chromosome with the additional –sex flag in PLINK. We are 80% 
powered to detect a relative difference of 4% or more (i.e. an OR of 1.04 or 0.96 assuming a MAF 
0.1, P = 5 x 10-8).  Sex-specific GWAS were performed in PLINK 1.9 using logistic regression 
stratified by sex adjusting for age, 10 principal components of ancestry, and genotyping array. We 
used a hard-call genotype threshold of 0.1, SNP imputation quality threshold of 0.80, and a MAF 
threshold of 0.001. SNP x sex interactions (13 tests) and SNP x menopause interaction in females 
(13 tests) were tested for genome-wide significant signals with the significance threshold defined 
by Bonferroni correction. SNP-based trait heritability was calculated as the proportion of trait 
variance due to additive genetic factors measured in this study using BOLT-REML30, to leverage 
the power of raw genotype data together with low frequency variants (MAF ≥ 0.001). Additional 
independent risk loci were identified using the approximate conditional and joint association 
method implemented in GCTA (GCTA-COJO)53.  Fixed effects meta-analysis was performed 
using METAL54 with the standard error scheme.     
 
  
Sensitivity analyses on top signals. Follow-up analyses on genome-wide significant loci in the 
primary analyses included covariate sensitivity analysis individually adjusting for sleep apnea, 
coffee/tea intake, physical activity, severe stress, depression, psychiatric medication use, socio-
economic status, smoking, employment and marital status, and snoring, or BMI in addition to 
baseline adjustments for age, sex, 10 PCs and genotyping array. Sensitivity and sex-specific 
analyses were conducted only in unrelated subjects of white British ancestry.  
 
Gene, pathway and tissue-enrichment analyses. Gene-based analysis was performed using 
PASCAL26. Tissue enrichment analysis was conducted using FUMA55. Enrichment for pathways 
and ontologies was performed in EnrichR33,34 using the human genome as the reference set and a 
minimum number of 2 genes per category. A genetic risk score for RLS was tested using the 
weighted genetic risk score calculated by summing the products of the RLS risk allele count for 
20 genome-wide significant SNPs multiplied by the scaled RLS effect reported by Schormair et 
al.35 using the summary statistics from our frequent insomnia symptom GWAS using the GTX 
package in R56. Integrative transcriptome-wide association analyses with GWAS were performed 
using the FUSION TWAS package29 with weights generated from gene expression in 8 brain 
regions and 6 tissues from the GTEX consortium (v6) , and SNPs common to the 1000 Genomes 
LD reference panel and our frequent insomnia symptoms GWAS summary statistics. Tissues for 
TWAS testing were selected from the FUMA tissue enrichment analyses and here we present 
significant results that survive Bonferroni correction for the number of genes tested per tissue and 
for all 14 tissues. In the results table, we show the number of individuals per tissue type used to 
generate expression weights, the total number of genes expressed per tissue, gene symbol for 
significant gene, rsID for the best GWAS and eQTL SNPs in the reference panel, and the TWAS 
P value. GWAS and eQTL SNPs analyzed include only those SNPs present in the 1000 Genomes 
LD reference panel used by the FUSION TWAS software; therefore, the best GWAS SNP listed 
in this table may be in  strong linkage disequilibrium with, but not identical to, the lead GWAS 
SNP for hits in Supplementary Table 2. 
 
Heterogeneity analysis. Analyses to distinguish pleiotropy and heterogeneity between insomnia 
and RLS was performed using Breaking Up Heterogeneous Mixture Based On Cross-locus 
correlations (BUHMBOX)41. BUHMBOX analyses tests the presence of heterogeneity between 
two traits.  BUHMBOX was performed in the insomnia GWAS using all 20 RLS SNPs and weights 
reported by Schormair et al.35 and in the RLS GWAS using all 57 SNPs reported in Supplementary 
Table 2.  Additional sensitivity analyses were performed excluding SNPs in the MEIS1 region.   
 
Genetic correlation analyses. Post-GWAS genome-wide genetic correlation analysis of LD 
Score Regression (LDSC)32,42,43 using LDHub was conducted using all UK Biobank SNPs also 
found in HapMap3 and included publicly available data from 224 published genome-wide 
association studies, with a significance threshold of P = 0.002 after Bonferroni correction for all 
tests performed. LDSC estimates genetic correlation between two traits from summary statistics 
(ranging from -1 to 1) using the fact that the GWAS effect-size estimate for each SNP incorporates 
effects of all SNPs in LD with that SNP, SNPs with high LD have higher X2 statistics than SNPs 
  
with low LD, and a similar relationship is observed when single study test statistics are replaced 
with the product of z-scores from two studies of traits with some correlation. Furthermore, genetic 
correlation is possible between case/control studies and quantitative traits, as well as within these 
trait types. We performed partitioning of heritability using the 8 pre-computed cell-type regions, 
and 25 pre-computed functional annotations available through LDSC, which were curated from 
large-scale robust datasets31. Enrichment both in the functional regions and in an expanded region 
(+500 bp) around each functional class was calculated in order to prevent the estimates from being 
biased upward by enrichment in nearby regions. The multiple testing threshhold for the 
partitioning of heritability was determined using the conservative Bonferroni correction (P of 
0.05/25 classes). Summary GWAS statistics will be made available at the UK Biobank web portal.  
 
Mendelian randomization analyses. MR analysis was carried out using MR-Base57,  using the 
inverse variance weighted approach as our main analysis method44, and MR-Egger45 and weighted 
median estimation46 as sensitivity analyses. MR results may be biased by horizontal pleiotropy, 
i.e. where the genetic variants that are robustly related to the exposure of interest (here frequent 
insomnia symptoms) independently influence levels of a causal risk factor for the outcome. IVW 
assumes that there is no horizontal pleiotropy. MR-Egger provides unbiased causal estimates even 
if all of the genetic instruments have horizontal pleiotropic effects, but it assumes that the 
association of genetic instruments with risk factor is not correlated with any pleiotropic genetic 
instrument associations with outcome. The weighted median approach is valid if less than 50% of 
the weight is pleiotropic (i.e. no single SNP that contributes 50% of the weight or a number of 
SNPs that together contribute 50% should be invalid because of horizontal pleiotropy. Given these 
different assumptions, if all three methods are broadly consistent, this strengthens our causal 
inference. For most of our MR analyses, we used two-sample MR, in which, for all 57 of the 
insomnia GWAS hits identified in this study, we looked for the per allele difference in odds (binary 
outcomes) or means (continuous) with outcomes from summary publicly available data in the MR-
Base platform. Results are therefore a measure of ‘any insomnia’ and sample 1 is UK Biobank 
(our GWAS) and sample 2 a number of different GWAS consortia covering the outcomes we 
explored (Supplementary Table 17). For all four of the longevity outcomes and as follow up for 
CAD, we used one-sample MR with the SNP-outcome associations also obtained from UK 
Biobank. If we could not find one of the 57 SNPs in the outcome database we substituted for a 
proxy where possible, LD proxies are defined using 1000 Genomes European sample with r2 > 
0.8. The number of SNPs used in each MR analysis varies by outcome from 11 to 53 because of 
some SNPs (or proxies for them) not being located in the outcome GWAS (Table 1).  
Primary association analyses of the 57 genome-wide significant insomnia SNPs with CAD 
were performed in Hail (https://github.com/hail-is/hail) using imputed genotype dosages and a 
logistic regression model adjusting for age at first visit, sex, genotyping array, and the first 10 
principal components of ancestry. A total of 23,980 CAD cases were compared to 388,326 
referents. For Mendelian randomization, a fixed-effects inverse-variance weighted meta-analysis 
was performed of the SNP-specific association estimates with CAD, aligning each insomnia SNP 
allele/beta coefficient to “increased risk of insomnia.” Sensitivity analyses were performed 
excluding the variants with the strongest effect estimate and/or widest confidence intervals to 
account for SNP heterogeneity. 
 
  
Replication cohort. Replication cohort sample ascertainment, phenotype definition, genotyping, 
quality control, imputation, and analyses are described in the Supplementary Note. 
 
Reporting summary. An accompanying Life Sciences Reporting Summary is published along 
with this manuscript. 
 
Data availability. GWAS summary statistics are available at the Sleep Disorders Knowledge 
Portal data download page (http://sleepdisordergenetics.org/informational/data). 
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Editorial summary: 
 
 
Genome-wide association analyses identify 57 loci associated with insomnia symptoms and 
evidence of shared genetic architecture between insomnia and cardio-metabolic, behavioral, 
psychiatric and reproductive traits.
  
 
